MetaCap

Mesoblast Limited ADR (MESO)

NASDAQ: MESOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

10.89-0.29 (-2.59%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

MESO stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$0.44
52-week range
10.87 – 21.50
Day range
10.87 – 11.44
Volume / Avg
192.70K / 240.68K
Beta
—

52-week range

$10.87$21.50

MESO stock today

On Nov 20, MESO ended the session at $10.89, shedding $0.29 (2.59%), versus the S&P 500's 3.70% decline. At this level, MESO sits near the bottom of its 52-week range of $10.87 to $21.50: 49.3% below the high, set on Jan 9, 2026 and 0.2% above the low. MESO is down 39.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 29.1%.

Mesoblast has posted a net loss over the last twelve months (EPS of -$0.44), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Mesoblast

Company profile

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Ryoncil for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)
Headquarters
Melbourne, VIC
Employees
108
IPO year
2015

Financial highlights

Full financials

In fiscal 2025, Mesoblast generated $17.2 million in revenue, up 191.4% from fiscal 2024. Mesoblast reported a net loss of $102.1 million, compared with a loss of $88.0 million a year earlier. Gross margin was 70.2% (down from 100.0%).

Mesoblast annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$17.20M$5.90M$7.50M$10.21M$7.43M
Growth+191.39%-21.32%-26.54%+37.36%-76.88%
Net income$-102.14M$-87.96M$-81.89M$-91.35M$-98.81M
EPS (diluted)$-0.0846$-0.0891$-0.1053$-0.1338$-0.1633

Analyst forecast

Forecast

Consensus (3 analysts)

none

Avg. price target

$37.00+239.76%

  • Strong buy 2
  • Buy 1
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $35.00High $39.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

MESO news

All MESO news

Mesoblast peers

Health Care sector
MESO peer companies
CompanyPrice% ChgMarket capCompare
WWBWindward Bio Group AG24.29+1.15%$1.45Bvs MESO
IMCRImmunocore Holdings plc ADR26.41-0.83%$1.36Bvs MESO
ALVOAlvotech4.12-3.96%$1.47Bvs MESO
RXRXRecursion Pharmaceuticals Inc. Class A2.45-9.93%$1.53Bvs MESO
VIRVir Biotechnology Inc.8.39-5.41%$1.56Bvs MESO
NVAXNovavax Inc.7.47-3.24%$1.23Bvs MESO
TSHATaysha Gene Therapies Inc.3.72-1.33%$1.21Bvs MESO
VORVor Biopharma Inc.19.19+3.62%$1.18Bvs MESO

Indexes, lists and sector

Mesoblast stock FAQ

What is Mesoblast's stock price today?

MESO last traded at $10.89 as of Nov 20, 4:00 PM EST, down 2.59% on the day. Prices are delayed at least 15 minutes.

Does Mesoblast pay a dividend?

No. Mesoblast does not currently pay a regular cash dividend.

Who is Mesoblast's CEO?

Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) is the chief executive officer of Mesoblast Limited ADR, which has about 108 employees.

Has MESO ever split its stock?

Yes. The most recent MESO stock split was a 1-for-2 split on Jan 10, 2024.

What is the MESO 52-week high?

The 52-week high for MESO is $21.50 and the 52-week low is $10.87. The stock is currently 49.3% below its high.

Compare MESO